Curated News
By: NewsRamp Editorial Staff
June 28, 2024
Tiziana Life Sciences CEO Discusses Advancements in Neurodegenerative Disease Treatments
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Investing in Tiziana Life Sciences' innovative intranasal antibody treatment could provide a competitive advantage in the neurodegenerative disease market.
- Tiziana Life Sciences is developing a fully human CD3 monoclonal antibody, delivered intranasally, specifically targeting neurodegenerative diseases such as MS and Alzheimer's.
- The advancements made by Tiziana Life Sciences in treating neurodegenerative diseases have the potential to improve the lives of patients and make tomorrow better than today.
- Tiziana Life Sciences is exploring the combination of its drug with GLP-1 antagonists to target obesity-related diseases, offering an interesting approach to tackling health issues.
Impact - Why it Matters
This news matters as Tiziana Life Sciences' advancements in neurodegenerative disease treatments, including MS and Alzheimer's, have the potential to significantly impact patient outcomes and offer hope for those suffering from these conditions. The company's progress in securing funding also demonstrates its commitment to advancing these important treatments.
Summary
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chairman and CEO Gabriele Cerrone discussed the company's recent advancements, including the development of a fully human CD3 monoclonal antibody targeting neurodegenerative diseases such as multiple sclerosis (MS) and Alzheimer's disease. The company is making progress in MS treatments with an expanded access trial at Harvard University's Brigham and Women's Hospital, where 70% of patients showed improvement in fatigue scores and 80% experienced reduced brain inflammation. Tiziana Life Sciences is also preparing to dose the first Alzheimer's patients in a new FDA-approved trial, and exploring the combination of its drug with GLP-1 antagonists to target obesity-related diseases. The company secured $3.4 million in non-dilutive funding, emphasizing its commitment to protecting shareholder investments.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Tiziana Life Sciences CEO Discusses Advancements in Neurodegenerative Disease Treatments
